(SGHT) Sight Sciences - Ratings and Ratios

Sight Sciences, Inc. (NASDAQ:SGHT) is a medical device company specializing in ophthalmic technologies for eye diseases, particularly glaucoma and dry eye conditions. The company operates through two primary segments: Surgical Glaucoma and Dry Eye. Its product portfolio includes the OMNI Surgical System, a microinvasive glaucoma surgery (MIGS) device designed to reduce intraocular pressure without implants; the SION Surgical Instrument, a manual device for excising trabecular meshwork during glaucoma surgery; and the TearCare System, a wearable technology for managing evaporative dry eye caused by meibomian gland dysfunction. The company distributes its products through a network of sales representatives and distributors, targeting hospitals, medical centers, and eyecare professionals in the United States. Founded in 2010, Sight Sciences is headquartered in Menlo Park, California, and is known for its focus on minimally invasive and non-invasive solutions in ophthalmology.

From a financial perspective, Sight Sciences operates with a market capitalization of $133.56 million. The companys price-to-sales ratio stands at 1.68, reflecting its revenue generation relative to market valuation. However, the return on equity (RoE) is negative at -53.03%, indicating current profitability challenges. The stock is traded on the NASDAQ under the ticker symbol SGHT, with an average 20-day trading volume of 262,836 shares. Recent price action shows the stock trading at $2.47, below its 20-day SMA of $2.66 and 50-day SMA of $3.00, suggesting bearish momentum. The 200-day SMA of $5.18 highlights a significant decline over the past year. The average true range (ATR) of 0.19 indicates moderate volatility.